SEC Form 4 · accession 0001437749-26-030593
PUMA BIOTECHNOLOGY, INC. · PBYI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alessandra Cesano
Director
Period of report
Sep 14, 2026
Accepted (ET)
Sep 16, 2026 · 9:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001401667
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 14, 2026 | M | 50,000 | $2.93 | A | 118,850 | D | |
| Common StockF2 | Sep 14, 2026 | S | 62,150 | $9.123 | D | 56,700 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3 | $2.93 | Sep 14, 2026 | M | 50,000 | D | — | Jul 28, 2032 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Adoption date of referenced 10b5-1(c) plan is: 06-15-2026
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.2, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3The Stock Option is fully vested.